September 10, 2024 03:35 PM EDTUpdated 06:19 PM
R&D
Pharma

Adicet fol­lows oth­er cell ther­a­py biotechs in au­toim­mune piv­ot

Max Bayer

Pharma Reporter

Adicet Bio is shelv­ing plans to use its lead as­set to treat can­cer and in­stead shift­ing its tar­get to au­toim­mune dis­eases.

The move, dis­closed by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times